register

Digital & Innovation

ASX-listed digital health company to harness AI in Alzheimer’s and dementia diagnosis

Health Industry Hub | June 6, 2024 |

Digital Health & Innovation: An ASX-listed digital healthcare company, specializing in AI-driven diagnostics for neurological disorders, is participating in a clinical study aimed at enhancing the early and accurate diagnosis of dementia, specifically frontotemporal dementia (FTD) and Alzheimer’s Disease (AD), through innovative AI-powered diagnostic tools.

Partnering with Erasmus University Medical Centre (Erasmus MC) in Rotterdam, BlinkLab will leverage its cutting-edge AI technology within the newly established Digital Dementia Lab. This lab serves as a home-based testing environment designed to develop and assess digital biomarkers, focusing on clinically relevant behaviours to improve early diagnosis of Alzheimer’s and dementia.

The partnership grants BlinkLab an exclusive option to license any new intellectual property arising from the study.

Henk-Jan Boele, CEO of BlinkLab, stated “This work will be an important driver for the transformation of mental healthcare from the current one-size-fits-all approach to a data-driven, personalised, and affordable system. I am looking forward to working with Dr Jackie Poos and we are confident that our collaboration will offer new possibilities for the advancement of dementia diagnosis and care.”

Brian Leedman, Chairman of BlinkLab, echoed the sentiment, emphasizing the strategic significance of partnering with a top-tier research institution like Erasmus MC. He stated, “This collaboration validates our innovative solutions and underscores the potential of our technology to revolutionise the diagnosis and management of dementia, complementing our ongoing work in autism and ADHD.”

In recent years, BlinkLab has made significant strides in developing a smartphone-based diagnostic platform for various neuropsychiatric conditions, including autism, ADHD, and schizophrenia.

Their most advanced product is an autism diagnostic test leveraging smartphones, AI, and machine learning, specifically designed for children as young as 18 months old. This advancement is crucial, considering traditional diagnoses typically occur around five years of age, often missing the critical early intervention window.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Clinicians unveil Novartis and BMS practice-changing trial results

Clinicians unveil Novartis and BMS practice-changing trial results

Health Industry Hub | June 24, 2024 |

Pharma News: Australia, known for its alarming melanoma rates, witnesses one person diagnosed with the disease every 30 minutes, and […]

More


News & Trends - Pharmaceuticals

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Health Industry Hub | June 24, 2024 |

Pharma News: Heart failure is a significant health concern in Australia, affecting approximately half a million people, with over 67,000 […]

More


News & Trends - MedTech & Diagnostics

Cardiologists mark Australian first with Boston Scientific's intracoronary imaging system

Cardiologists mark Australian first with Boston Scientific’s intracoronary imaging system

Health Industry Hub | June 24, 2024 |

MedTech & Diagnostics News: Percutaneous coronary intervention (PCI) has faced substantial complications and failure rates, despite advances in medical devices […]

More


Leadership & Management

AbbVie New Zealand welcomes new leadership amid global moves

AbbVie New Zealand welcomes new leadership amid global moves

Health Industry Hub | June 24, 2024 |

Leadership & Management: In line with its global talent development plan, AbbVie has announced a significant change in leadership for […]

More


This content is copyright protected. Please subscribe to gain access.